Day: March 4, 2024

MEDIA RELEASECIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indications Dedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for providers and patientsBasel, March 4, 2024 – Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar CIMERLI®* (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of anticipated timelines. The acquisition builds on the leading Sandoz ophthalmic platform in the US and lays an even stronger foundation for future product launches. Keren Haruvi, President Sandoz North America said: “Today we further expand the Sandoz biosimilar portfolio, while advancing our mission in the US of pioneering patient access to more affordable and much-needed...

BILBAO, Spain and Orlando, FLORIDA March 4, 2024.– John A. Cunningham has been appointed President of Virtualware USA operations, as Virtualware (EPA: MLVIR), the European leader in enterprise Virtual Reality solutions, starts operations in the country. As announced recently, expanding into the United States is an important element in the company’s 2024-2026 strategy.  Around 40% of the company’s total 2023 signed contracts value came from the U.S In the spirit of this strategy, Virtualware aims to expand its presence in the U.S. market to support existing customers and cultivate a robust ecosystem of partners to create innovative training solutions for enterprise customers. Cunningham will start his tenure immediately and begin working with partners and clients alike to reinforce Virtualware’s stance in crucial sectors,...

The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies 1-6 Nearly all patients treated maintained or improved motor milestones after 52 weeks, with most switching to the one-time gene therapy from another chronically administered disease-modifying therapy 1-6 The SMART study is the first open-label clinical study of Zolgensma to include previously treated patients 1-6Basel, March 4, 2024 – Novartis today presented new data that continue to support the clinical benefits of Zolgensma® (onasemnogene abeparvovec), the only one-time gene therapy for the treatment of spinal muscular atrophy (SMA). Final data from the SMART study highlight the safety and efficacy profile of Zolgensma in children...

CORAL GABLES, Fla., March 03, 2024 (GLOBE NEWSWIRE) — Coral Gables, FL, March 3, 2024. MSP Recovery, Inc. d/b/a LifeWallet (NASDAQ: LIFW) (“LifeWallet” or “the Company”) announces a comprehensive settlement with 28 affiliated property and casualty insurers (“P&C Insurers”) that, in addition to settling existing claims, establishes a going-forward process to collaboratively and timely resolve future claims, as well as share important historical data that is expected to enhance LifeWallet’s claims reconciliation capabilities, benefiting its Medicare clients across the mainland U.S. and Puerto Rico. The settlement includes:The P&C Insurers’ agreement to provide ten years of historical data (identifying all claims processed from January 1, 2014, through the present) and data sharing of future claims, extending out for one...